A cocktail of four oral drugs, caffeine (CYP1A2), chlorzoxazone (CYP2E1), debrisoquin (CYP2D6), and mephenytoin (CYP2C19), were administered to 20 patients with different severity of liver disease and 20 health-matched controls. The gene discussed is CYP2C19; the disease is liver disorder.